ICH – Page 8 – Pharma.Tips

Species selection questioned during regulatory submission prep – preventing clinical hold

Addressing Concerns Over Species Selection in Regulatory Submissions to Avoid Clinical Holds During the drug development process, the selection of species for preclinical studies plays a crucial role, especially during…

Study design not regulator-aligned during program hold risk review – how to defend preclinical package

Defending Preclinical Packages Against Non-Alignment with Regulatory Study Design During Risk Reviews In the complex landscape of pharmaceutical development, the alignment of study design with regulatory expectations is critical, particularly…

Reproducibility gaps during sponsor oversight – FDA/EMA non-clinical expectations

Addressing Reproducibility Gaps in Sponsor Oversight for Non-Clinical Studies In the realm of pharmaceutical development, reproducibility gaps during sponsor oversight can severely undermine the integrity and reliability of preclinical studies.…

Reproducibility gaps during sponsor oversight – FDA/EMA non-clinical expectations

Addressing Reproducibility Gaps in Sponsor Oversight for Non-Clinical Studies In the realm of pharmaceutical research and drug development, reproducibility is a critical factor that can significantly influence regulatory acceptance and…

Reproducibility gaps during program hold risk review – CAPA for study design gaps

Addressing Reproducibility Issues During Program Hold Risk Reviews: Effective CAPA for Study Design Gaps In the dynamic landscape of pharmaceutical research, reproducibility gaps during program hold risk reviews can significantly…

GLP readiness concerns during IND-enabling studies – FDA/EMA non-clinical expectations

Addressing GLP Readiness Issues During IND-Enabling Studies: An Investigation Framework In the landscape of pharmaceutical research, the transition from preclinical data to Investigational New Drug (IND) applications is critical. However,…

Species selection questioned during study audit – preventing clinical hold

Evaluating Species Selection during Preclinical Audits to Prevent Clinical Holds During preclinical research, a variety of challenges may arise that could jeopardize the progression of a drug development project. One…

Reproducibility gaps during study audit – how to defend preclinical package

Identifying and Addressing Reproducibility Gaps in Preclinical Study Audits Reproducibility gaps during study audits can have significant impacts on preclinical packages, potentially affecting the trajectory of drug discovery and regulatory…

Study design not regulator-aligned during regulatory submission prep – how to defend preclinical package

How to Address Study Design Misalignments During Regulatory Submission Preparations In an environment where regulatory compliance is critical, misalignment between study design and regulatory expectations can lead to significant setbacks.…

GLP readiness concerns during sponsor oversight – how to defend preclinical package

Addressing GLP Readiness Challenges during Sponsor Oversight in Preclinical Packages In the realm of pharmaceutical development, ensuring compliance with Good Laboratory Practices (GLP) is paramount, especially when oversight by sponsors…

Species selection questioned during program hold risk review – CAPA for study design gaps

Investigating Species Selection Questions During Program Hold Risk Reviews In the fast-evolving landscape of pharmaceutical research, one of the critical components of successful drug development is the selection of appropriate…

Study design not regulator-aligned during program hold risk review – FDA/EMA non-clinical expectations

Investigating Misalignment in Study Design During Program Hold Risk Review In the complex landscape of pharmaceutical development, study design that does not align with regulatory expectations from the FDA and…